



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 56087

**Title:** Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report

**Reviewer's code:** 03505873

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Research Assistant Professor

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** China

**Manuscript submission date:** 2020-05-12

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-05-12 17:33

**Reviewer performed review:** 2020-05-16 06:14

**Review time:** 3 Days and 12 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

In this manuscript, the authors report a case study of lung adenocarcinoma harboring a complex EGFR mutation (L858R/V834L). They demonstrate that the cancer with the complex mutation responded well to the EGFR tyrosine kinase inhibitor icotinib. In general, the finding is consistent with what was found previously, therefore, this study may be potentially helpful to the treatment of similar cancer patients in the future. Major concerns 1. H&E of the cancer tissue and immunohistochemistry staining of EGFR may be provided. 2. High resolution image of NGS analysis and CT image should be presented to clearly show the mutation types and frequencies; and the response of cancer to TKI inhibitor treatment.



**RE-REVIEW REPORT OF REVISED MANUSCRIPT**

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 56087

**Title:** Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report

**Reviewer’s code:** 03505873

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Research Assistant Professor

**Reviewer’s Country/Territory:** United States

**Author’s Country/Territory:** China

**Manuscript submission date:** 2020-05-12

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-07-21 15:25

**Reviewer performed review:** 2020-07-22 01:44

**Review time:** 10 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

My questions have been well addressed.